Safety and Efficacy Study of Rituximab in Renal Transplantation
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
Current strategies for the medical management of transplant patients are largely focused on
the prevention and treatment of T-lymphocyte mediated processes. However there is an
increasing evidence to suggest that B-lymphocytes have a role in the otherwise classic T-cell
mediated rejection of transplants by there ability to act as antigen presenting cells and
T-cell activators. Thus there is a significant medical need for effective therapies targeting
B cells of transplant patients.One such potential therapy would be to use rituximab, a
monoclonal antibody against B-cells in all renal transplant patients. In the present study
the efficacy and safety of prophylactic rituximab is studied.